Based on an integrated analysis of LC-MS metabolomics and pharmacogenomics on HCT116 cells, KA treatment was found to inhibit CRC via suppressing glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-mediated glycolysis, revealing that targeting glucose metabolism may be a potential therapy for CRC (Liberti et al., 2017). Here, GAPDH is linked to colorectal carcinoma.